Our Tests

Our goal is to ensure you have the most accurate information and the best possible options to make informed decisions about your cancer treatment and care. Explore our services to discover how we can support you on your path to a better outcome.

Cancer Marker Panel DNA and RNA:

DNA Based Assays:

ABL2, ACVR1, ACVR1B, ADGRA2, AKT1, AKT2, ALOX12B, AMER1, ANKRD11, ANKRD26, APC, ARAF, ARFRP1, ARID1A, ARID1B, ARID2, ARID5B, ASXL1, ASXL2, ATM, ATR, ATRX, AURKA, AURKB, AXIN1, AXIN2, B2M, BAP1, BARD1, BBC3, BCL10, BCL10, BCL2L1, BCL2L11, BCL2L2, BCL6, BCOR, BCORL1, BCR, BIRC3, BLM, BMPR1A, BRD4, BRIP1, BTG1, BTK, CALR, CARD11, CASP8, CBFB, CBL, CCND1, CCND2, CCND3, CCNE1, CD274, CD276, CD74, CD79A, CD79B, CDC73, CDH1, CDK12, CDK6, CDK8, CDKN1A, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CEBPA, CENPA, CHD2, CHD4, CHEK1, CHEK2, CIC, COP1, CREBBP, CRKL, CRLF2, CSF3R, CSNK1A1, CTCF, CTLA4, CTNNA1, CTNNB1, CUL3, CUX1, CXCR4, CYLD, DAXX, DCUN1D1, DDR2, DDX41, DHX15, DICER1, DIS3, DNAJB1, DNMT1, DNMT1, DNMT3A, DNMT3B, DOT1L, E2F3, EED, EGFL7, EIF1AX, EIF4A2, EIF4E, ELOC, EMSY, EP300, EPCAM, EPHA3, EPHA5, EPHA7, EPHB1, ERBB3, ERBB4, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, ERRFI1, ETV6, EZH2, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCI, FANCL, FAS, FAT1, FBXW7, FGF1, FGF10, FGF14, FGF19, FGF2, FGF23, FGF3, FGF4, FGF5, FGF6, FGF7, FGF8, FGF9, FH, FLCN, FLT4, FOXA1, FOXL2, FOXO1, FOXP1, FRS2, FUBP1, FYN, GABRA6, GATA1, GATA2, GATA3, GATA4, GATA6, GEN1, GEN1, GID4, GLI1, GNA11, GNA13, GNAQ, GNAS, GPS2, GREM1, GRIN2A, GRM3, GSK3B, H3F3A, H3F3B, H3F3C, HGF, HIST1H1C, HIST1H2BD, HIST1H3A, HIST1H3B, HIST1H3C, HIST1H3D, HIST1H3E, HIST1H3F, HIST1H3G, HIST1H3H, HIST1H3I, HIST1H3J, HIST2H3A, HIST2H3C, HIST2H3D, HIST3H3, HLA-A, HLA-B, HLA-C, HLA-C, HNF1A, HNRNPK, HOXB13, HRAS, HSD3B1, HSP90AA1, ICOSLG, ID3, IDH1, IDH2, IFNGR1, IGF1, IGF1R, IGF2, IKBKE, IKZF1, IL10, IL7R, INHA, INHBA, INPP4A, INPP4B, INSR, IRF2, IRF4, IRS1, IRS2, JAK1, JAK3, JUN, KAT6A, KDM5A, KDM5C, KDM6A, KDM6A, KEAP1, KEL, KLF4, KLHL6, KMT2B, KMT2C, KMT2D, KRAS, LAMP1, LATS1, LATS2, LMO1, LRP1B, LYN, LZTR1, MAGI2, MALT1, MAP2K1, MAP2K2, MAP2K4, MAP3K1, MAP3K13, MAP3K14, MAP3K4, MAPK1, MAPK3, MAX, MCL1, MDC1, MDM2, MDM4, MED12, MEF2B, MEN1, MEN1, MGA, MITF, MLH1, MPL, MRE11, MSH3, MSH6, MST1, MST1R, MTOR, MUTYH, MYB, MYCL, MYCN, MYD88, MYOD1, NAB2, NBN, NCOA3, NCOR1, NEGR1, NF1, NF2, NFE2L2, NFKBIA, NKX2-1, NKX3-1, NOTCH4, NPM1, NRAS, NSD1, NUP93, NUTM1, PAK1, PAK1, PAK3, PAK5, PALB2, PARP1, PAX5, PAX8, PBRM1, PDCD1, PDCD1LG2, PDK1, PDPK1, PGR, PHF6, PHOX2B, PIK3C2B, PIK3C2G, PIK3C3, PIK3CB, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIK3R3, PIM1, PLCG2, PLK2, PMAIP1, PMS1, PMS2, PNRC1, POLD1, POLE, PPM1D, PPP2R1A, PPP2R1A, PPP2R2A, PPP6C, PRDM1, PREX2, PRKAR1A, PRKCI, PRKDC, PRKN, PRKN, PTCH1, PTEN, PTPN11, PTPRD, PTPRS, PTPRT, QKI, RAB35, RAC1, RAD21, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD52, RAD54L, RANBP2, RARA, RASA1, RB1, RBM10, RECQL4, REL, RHEB, RHEB, RHOA, RICTOR, RIT1, RNF43, RPS6KA4, RPS6KB2, RPTOR, RUNX1, RUNX1, RYBP, SDHA, SDHAF2, SDHB, SDHC, SDHD, SETBP1, SETD2, SF3B1, SH2B3, SH2D1A, SHQ1, SLIT2, SLX4, SMAD2, SMAD3, SMAD4, SMARCA4, SMARCB1, SMARCD1, SMC1A, SMC3, SMO, SNCAIP, SOCS1, SOCS1, SOX10, SOX17, SOX2, SOX9, SPEN, SPOP, SPTA1, SRC, SRC, STAG1, STAG2, STAT3, STAT4, STAT5A, STAT5B, STK11, STK40, SUFU, SUZ12, SYK, TAF1, TBX3, TCF3, TCF7L2, TENT5C, TERC, TERT, TET1, TET2, TFE3, TFRC, TGFBR1, TGFBR2, TMEM127, TMEM127, TNFAIP3, TNFRSF14, TOP1, TOP2A, TP53, TP63, TRAF2, TRAF7, TRAF7, TSC2, TSHR, U2AF1, VEGFA, VHL, VTCN1, WISP3, WT1, XIAP, XPO1, XRCC2, YAP1, YES1, ZBTB2, ZBTB7A, ZFHX3, ZNF217, ZNF703, ZRSR2

RNA Based Assays

ABL1, ALK, AR, AXL, BCL2, BRAF, BRCA1, BRCA2, CDK4, CSF1R, EGFR, EML4, ERBB2, ERG, ESR1, ETS1, ETV1, ETV4, ETV5, EWSR1, FGFR1, FGFR2, FGFR3, FGFR4, FLI1, FLT1, FLT3, JAK2, KDR, KIF5B, KIT, KMT2A, MET, MLLT3, MSH2, MYC, NOTCH1, NOTCH2, NOTCH3, NRG1, NTRK1, NTRK2, NTRK3, PAX3, PAX7, PDGFRA, PDGFRB, PIK3CA, PPARG, RAF1, RET, ROS1, RPS6KB1, TMPRSS2

Synonyms: Genetic Cancer Panel, DNA Panel, Next-Generation Sequencing (NGS) Panel, Oncogenetic Testing, Cancer Marker Panel (DNA/RNA)

Description of the Test:

DNA Panel Analysis involves the examination of over 500 genes associated with cancer using next-generation sequencing technologies. This comprehensive genetic assessment provides insights into the genetic mutations and alterations linked to cancer, aiding in the selection of targeted and personalized treatment options.

The DNA Panel Analysis is a state-of-the-art genetic test designed to identify mutations and alterations in a broad array of cancer-related genes. Utilizing advanced next-generation sequencing (NGS) technology, this test analyzes more than 500 genes known to be implicated in various types of cancer. The results facilitate the selection of the most effective and personalized treatment strategies based on the specific genetic profile of the tumor.

Purpose of the Test:

The DNA Panel Analysis provides a detailed genetic profile of cancer cells, guiding the choice of targeted therapies. It is essential for patients seeking personalized treatment options and can also help determine eligibility for specific clinical trials. By identifying key genetic mutations, this test supports the tailoring of treatment strategies to the individual’s unique genetic profile.

This test is a cornerstone of precision medicine, enabling clinicians to choose therapies that target the specific genetic changes present in cancer cells. This personalized approach not only enhances treatment efficacy but also reduces potential side effects by avoiding less effective therapies.

What we offer:

Our CAP/CLIA Next Generation Sequencing assay is a comprehensive test that covers both DNA sequencing (523 genes) and RNA sequencing (55 genes). 59 genes are measured for copy number variation (CNV). The assay is capable of >95% detection sensitivity of DNA variants down to 2.5% at standard (80ng) and low (40ng) input. The analysis also covers tumour mutational burden (TMB), microsatellite instability (MSI), and RNA fusions and mis-splicing.

Tests cover:

  • 523 genes implicated in various solid tumour types,

  • Simultaneous analysis of DNA and RNA, enabling highly sensitive review of fusions and splice variants,

  • Key immuno-oncology biomarker measurements include MSI, TMB, and appropriate markers by IHC.
    It's essential to understand the limitations of tumour testing. While testing can provide valuable information, it may not always yield actionable results. Results can be influenced by factors such as tumour heterogeneity and technical limitations of the testing method.

Immunohistochemistry

Possible Markers:

ALK*, AR, ER, FOLR1, HER2, Ki-67, MMR, p53, PD-L1*, PR, PTEN, ROS1, TS

*CDx Assays

Synonyms:

Diagnostic IHC Panel, Oncological Biomarker Panel, Comprehensive IHC Panel, Multi-Biomarker IHC Panel, Tumor Profiling Panel, Predictive and Therapeutic IHC Panel, Molecular Diagnostic Panel, Targeted Therapy IHC Panel, Prognostic IHC Panel

Description of the Test:

Immunohistochemistry (IHC) is a laboratory technique to examine the cellular components of a section of tissue sample (biopsy). IHC can detect the presence of specific protein markers that can assist with accurate tumor classification and diagnosis. Antigens are proteins that are within or on the surface of a cell. Pathologists look for the presence or absence of particular antigens to assist with a diagnosis. IHC uses antibodies to detect antigens in a tissue sample. The target antigen is a marker, indicating a specific disease is present. If the antibody recognizes the antigen, it will attach (bind) to it. If the antibody binds to the antigen, the tissue sample will stain a certain color when viewed with a microscope.

Purpose of the Test:

Used to check for signs of disease following a biopsy. IHC is commonly used to diagnose cancer, predict treatment response and determine likely outcomes (prognosis) of the disease.

Immunohistochemistry (IHC) can identify characteristics of tumour tissue that provide clues about how cancer may respond to treatment. For example, pathologists can identify cancer cells that are likely to grow in the presence of certain hormones. These cancers may respond best to treatments that block these hormones.

What we offer:

With a complete array of more than 250 Immunohistochemistry (IHC) antibodies and histochemical stains that serve as a diagnostic resource, we detect the presence, relative quantity, and localization of specific proteins to aid in determining differentiation in cancer cells to provide prognostic or therapeutic information.

Tests can cover:

  • An expansive menu available of immunohistochemistry tests including single antibodies and combinations

  • Multiple in-house testing platforms that tailor methodology to each case for the most detailed information

  • All major PD-L1 clones (22C3, 28.8, SP263, SP142) are available

  • Expertise in ER, PR, and HER2 staining and interpretation, including interpretation of “Low” HER2 staining cases

  • Extensive experience in interpretation of MMR, Ki-67 and p53 staining